Hansa Biopharma — Februar 2022
-
Decision to use commercially supplied Idefirix
(imlifidase) in approved indication by the European Medicines Agency (EMA)1,2-
Decision provides highly sensitized patients in France with the opportunity to immediately receive Idefirix
as desensitization treatment -
Commercial launch activities for Idefirix
in Europe continue to progress
-
-
Hansa Biopharma - Analyse fra H.C.Wainrigth&CO https://www.proinvestor.com/index.php?p=debat_1&postid=101507
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind